Extract

Dear Editor, Vitiligo is a common acquired skin disorder characterized by loss of skin pigmentation, significantly impacting patients’ quality of life.1 We previously showed that the oral Janus kinase (JAK) inhibitor baricitinib, in combination with narrowband ultraviolet B (NB-UVB), was an effective and safe treatment for progressive nonsegmental vitiligo.2 However, significant interpatient variability in response to this combination therapy has been observed, highlighting the need for reliable biomarkers to predict the efficacy of this combination in clinical practice. Data-independent acquisition (DIA)-based proteomics allows for the continuous and unbiased collection of secondary mass spectrometry (MS) data, making it one of the most widely utilized methods in clinical research.3 The collection of samples, such as blood and urine, is convenient and minimally invasive, facilitating the straightforward clinical translation and application of research findings. However, to date no studies have examined the plasma and urine proteomic profiles of patients receiving JAK inhibitors in conjunction with phototherapy.

You do not currently have access to this article.